The province of Limburg, through LBDF, has awarded CiMaas a subsidy for further development of the new technology for large scale production of NK cell immunotherapy. Under the subsidy, CiMaas collaborates with the department of Haematology of the MUMC+ and an American biotech company to further optimize the treatment.

Wilfred Germeraad, CSO of CiMaas: “The unique combination of technologies will provide the opportunity to produce these cells in very large quantities and is an important step in the development of a more effective treatment for cancer patients. The subsidy from LBDF significantly contributes to this development”.